Saturday, July 23, 2016 11:55:22 AM
I posted this Pharma Talk Radio conference before, sometime last year. Considering it's an interview with Roy Baynes it’s most appropriate to listen to it now to think about Combination starting at minute 13. And then make sure you listen to 16 mins: Immunogenic intensifying immune response. Then they speak about expression within the tumor. Basically, explains the rationale for combining immunotherapies, specifically PD1 and Vaccines are covered. Other interesting talks to listen to in the series. Enjoy. :)
Immuno-Oncology: Exploring the Challenges & Potential - See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf
Immuno-Oncology is arguably the most exciting area in the advancement of science and patient care today. However, with all research, there are plenty of challenges and to get a better understanding of this innovative approach to cancer research, we were pleased to welcome to Pharma Talk Radio, James Gulley, MD, PhD of the National Cancer Institute and Roy Baynes, MD, PhD at Merck Research Labs. Joining Drs Gulley and Baynes is Kate Woda, Director of the IO360 conference taking place at Columbia University Faculty House on June 29-30 in NYC. - See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf
Host:
Valerie Bowling, Producer, Pharma Talk Radio
Guests:
James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
Roy Baynes, MD, PhD, SVP, Global Clinical Development, Merck Research Labs
Kate Woda, Director, IO 360
The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.
- See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf
http://theconferenceforum.org/pharma-talk-radio/
Immuno-Oncology Drug Development: Challenges & Next Steps - See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf
More specifically they also address:
– Ipilumumab/Nivo/Pembro challenges
– What can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?
– Challenges with the following modalities: Checkpoints, Oncolytic Virus’, Adoptive T-Cells, Cancer Vaccines
– Blinitumumab
– The more interesting agents in late stage development now in immunotherapy and its promise
– Immune related adverse events
– Adoptive cellular therapies, what is the most promising?
– Will IO become backbone therapies for cancer?
– What’s the next set of assets that are going to come out?
– What can we expect within the next year or two?
Guests:
James Gulley, MD, PhD
Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
Axel Hoos, MD, PhD, VP, Oncology R&D, GlaxoSmithKline
The Immuno-Oncology 360° conference is scheduled for February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.
- See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf
http://theconferenceforum.org/pharma-talk-radio/
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM